No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PETQ240517P20000
- 3.70
- 0.000.00%
15min DelayClose Apr 15 11:32 ET
0.00High0.00Low
3.70Open3.70Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover260.00%IV-12.79%PremiumMay 17, 2024Expiry Date1.31Intrinsic Value100Multiplier8DDays to Expiry2.39Time Value100Contract SizeAmericanOptions Type-0.4892Delta0.0543Gamma5.05Leverage Ratio-0.1795Theta-0.0027Rho-2.47Eff Leverage0.0113Vega
Intraday
- 5D
- 1D
News
PetIQ | 10-Q: Quarterly report
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Petiq (PETQ) and Biodesix (BDSX)
Oppenheimer Sticks to Their Hold Rating for Petiq (PETQ)
Q1 2024 PetIQ Inc Earnings Call
PetIQ Expects Q2 Net Sales Of $325M-$335M (Est $335.976M), Raises FY24 Forecast From $1.130B-$1.180B To $1.135B-$1.185B (Est $1.149B)
For the second quarter of 2024 the Company expects: Adjusted EBITDA of $34.0 million to $36.0 million.For the full year 2024 the Company expects: Adjusted EBITDA of $112.0 million to $118.0 million.
Express News | PetIQ Inc Sees Q2 Adjusted Ebitda of $34.0 Million to $36.0 Million
Comments
Market expectations of PetIQ's future revenue decline could be suppressing the P/S ratio. With a lower growth forecast than the industry, it's understandable that PetIQ's P/S is below most companies. A strong share price rise seems unlikely under these circumstances.
Investors Don't See Light At End Of PetIQ, Inc.'s (NASDAQ:PETQ) Tunnel 1
Jefferies' analysts have faith in both Chewy and PetIQ as they are shielded from increasing pet care costs due to their strategic positions and target customer demographics. Expectations are high for Chewy's expansion in pet health and elsewhere, while PetIQ stands to gain from a rising focus on preventative pet health.
1
1
Both PetIQ's accrual ratio and its unusual items suggest that its statutory earnings are possibly conservative. Its potential to increase profit if unusual items do not reoccur indicates a hopeful future outlook.
Gainers:
In reaction to earnings/guidance:
• $The Trade Desk(TTD.US$+17%, $Workiva(WK.US$ +15.3%, $Arlo Technologies(ARLO.US$ +12%, $Array Technologies(ARRY.US$ +10.3%, $Everbridge(EVBG.US$ +9.7%, $Catalyst Pharmaceuticals(CPRX.US$ +9.4%, $Halozyme Therapeutics(HALO.US$ +8.7%, $Velo3D(VLD.US$ +7.6%, $CyberArk(CYBR.US$ + 6.2%, $Haemonetics(HAE.US$ +5.8%, $Jackson Financial(JXN.US$ +5.7% (also increases dividend), $Axon Enterprise(AXON.US$ +4.8%,...
In reaction to earnings/guidance:
• $The Trade Desk(TTD.US$+17%, $Workiva(WK.US$ +15.3%, $Arlo Technologies(ARLO.US$ +12%, $Array Technologies(ARRY.US$ +10.3%, $Everbridge(EVBG.US$ +9.7%, $Catalyst Pharmaceuticals(CPRX.US$ +9.4%, $Halozyme Therapeutics(HALO.US$ +8.7%, $Velo3D(VLD.US$ +7.6%, $CyberArk(CYBR.US$ + 6.2%, $Haemonetics(HAE.US$ +5.8%, $Jackson Financial(JXN.US$ +5.7% (also increases dividend), $Axon Enterprise(AXON.US$ +4.8%,...
11
2
CAN I AT LEAST LEARN HOW TO BUY N SELL STOCKS ON THIS Brokerage MOOMOO. 
FOR REAL I DONT GET IT 
Gainers：
• $Affirm Holdings(AFRM.US$ +36.4% (also announces multi-year extension of exclusive partnership with SHOP in the US)
• $Robinhood(HOOD.US$ +22.9% (Emergent Fidelity discloses 7.6% stake; Sam Bankman-Fried CEO of crypto exchange FTX is majority holder in fund)
• $Endeavor Group(EDR.US$ +20% (in reaction to earnings)
• $Coinbase(COIN.US$ +13% (in sympathy with HOOD news)
• $Dynavax Technologies(DVAX.US$ +11.5% (to join ...
• $Affirm Holdings(AFRM.US$ +36.4% (also announces multi-year extension of exclusive partnership with SHOP in the US)
• $Robinhood(HOOD.US$ +22.9% (Emergent Fidelity discloses 7.6% stake; Sam Bankman-Fried CEO of crypto exchange FTX is majority holder in fund)
• $Endeavor Group(EDR.US$ +20% (in reaction to earnings)
• $Coinbase(COIN.US$ +13% (in sympathy with HOOD news)
• $Dynavax Technologies(DVAX.US$ +11.5% (to join ...
27
2
Read more